Skip to main content
Contact Us
Subscribe
E-Edition
65°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coherus Bio
(NQ:
CHRS
)
2.000
-0.150 (-6.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Coherus Bio
< Previous
1
2
3
Next >
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
April 08, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
March 13, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
March 05, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Completes Divestiture of Ophthalmology Franchise
March 04, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
February 23, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
February 21, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
February 05, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
January 22, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
January 18, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces U.S. Launch of LOQTORZI™
January 02, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
December 26, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
December 11, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces CFO Transition Plans
December 07, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
December 06, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical
November 28, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
November 06, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
November 03, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences to Participate at Upcoming November Investor Conferences
November 02, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
October 30, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
October 27, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
October 24, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
October 05, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
October 04, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
October 02, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
September 27, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
September 25, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
September 22, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Completes Surface Oncology Acquisition
September 08, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.